CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Biogen Inc.

BIIB
$33.08BLarge Cap

Next catalyst

Phase 3December 2026

Felzartamab

Primary Membranous Nephropathy

Get an email about BIIB's next catalysts

Track Biogen (BIIB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 13 more upcoming events in our data (Phase 3 readout, Phase 2 readout).See the timeline

Catalyst Timeline

14 upcoming, 2 past

Phase 3Next

Felzartamab Phase 3 Est. Readout (TRANSCEND)

December 2026~Felzartamab132

Primary completion for Felzartamab trial (NCT06685757) in Antibody-mediated Rejection

Source
Phase 3

Lecanemab SC Phase 3 Est. Readout (Clarity AD)

December 2026~Lecanemab SC1,906

Estimated primary completion for Lecanemab SC trial (NCT03887455) in Early Alzheimer's Disease. Topline data typically follows completion by weeks to months.

Source
Phase 2

Tofersen Phase 2 Est. Readout

January 2027~Tofersen30

Estimated primary completion for Tofersen trial (NCT07294144) in ALS (Amyotrophic Lateral Sclerosis). Topline data typically follows completion by weeks to months.

Source
Phase 3

anti-TNF therapy Phase 3 Est. Readout (CRI-RA)

March 2027~anti-TNF therapy160

Estimated primary completion for anti-TNF therapy trial (NCT04870203) in Rheumatoid Arthritis. Topline data typically follows completion by weeks to months.

Source
Phase 3

BIIB017 (peginterferon beta-1a) Phase 3 Est. Readout

Q2 2027~QBIIB017 (peginterferon beta-1a)152

Primary completion for BIIB017 (peginterferon beta-1a) trial (NCT03958877) in Multiple Sclerosis, Relapsing-Remitting

Source
Phase 3

Felzartamab Phase 3 Est. Readout (PREVAIL)

Q2 2027~QFelzartamab454

Primary completion for Felzartamab trial (NCT06935357) in Immunoglobulin A Nephropathy (IgAN)

Source
Phase 2

APL-3007, pegcetacoplan (APL-2) Phase 2 Est. Readout

Q2 2027~QAPL-3007, pegcetacoplan (APL-2)240

Primary completion for APL-3007, pegcetacoplan (APL-2) trial (NCT07215390) in Geographic Atrophy Secondary to Age-related Macular Degeneration

Source
Phase 3

Pegcetacoplan Phase 3 Est. Readout

July 2027~Pegcetacoplan100

Primary completion for Pegcetacoplan trial (NCT05809531) in C3G

Source

How BIIB's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQBiological Products, (No Diagnostic Substances)Biotechnology🇺🇸North AmericaCAMBRIDGE7.5K employees

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate (Tecfidera), diroximel fumarate (Vumerity), interferon beta-1a (AVONEX), peginterferon beta-1a (Plegridy), and natalizumab (Tysabri), all for the treatment of multiple sclerosis (collectively 45% of 2024 revenues); nusinersen (Spinraza) for the treatment of spinal muscular atrophy (16.2% of 2024 revenues); omaveloxolone (Skyclarys) for the treatment of Friedreich's ataxia (4.0% of 2024 revenues); tofersen (Qalsody) for the treatment of ALS; and dimethyl fumarate (Fumaderm) for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars (8.2% of 2024 revenues) and has collaborations with Genentech for several drugs (18.1% of 2024 revenues).

Website
Drug Pipeline

Leqembi

Lecanemab

Approved

Alzheimer Disease

Fast TrackBreakthrough

Tofersen

Approved

ALS (SOD1)

OrphanFast TrackBreakthrough

Citalopram

Phase 3

Depressive Disorder, Major

APL2

Phase 3

FSGS

Lecanemab SC

Phase 3

Early Alzheimer's Disease

Lecanemab IV

Phase 3

Early Alzheimer's Disease

Pegcetacoplan

Phase 3

C3G

Dextromethorphan

Phase 3

Relapsing-Remitting Multiple Sclerosis

SAGE 217

Phase 3

Postpartum Depression

BIIB019 (Daclizumab)

Phase 3

Relapsing-Remitting Multiple Sclerosis

S-warfarin

Phase 3

Relapsing-Remitting Multiple Sclerosis

Avonex

Phase 3

Multiple Sclerosis

dimethyl fumarate

Phase 3

Relapsing-Remitting Multiple Sclerosis

Salanersen

Phase 3

Muscular Atrophy, Spinal

Midazolam

Phase 3

Relapsing-Remitting Multiple Sclerosis

natalizumab

Phase 3

Crohn's Disease

BG00012

Phase 3

Multiple Sclerosis

SAGE-217

Phase 3

Bipolar Disorder I

Litifilimab

Phase 3

Lupus Erythematosus, Systemic

Natalizumab (BG00002)

Phase 3

Multiple Sclerosis

BIIB017 (peginterferon beta-1a)

Phase 3

Multiple Sclerosis, Relapsing-Remitting

Felzartamab

Phase 3

Primary Membranous Nephropathy

Nusinersen

Phase 3

Muscular Atrophy, Spinal

BIIB017

Phase 3

Relapsing Multiple Sclerosis

BIIB041 (Fampridine-SR)

Phase 3

Multiple Sclerosis

peginterferon beta-1a

Phase 3

Relapsing Multiple Sclerosis

ALKS 8700

Phase 3

Relapsing Remitting Multiple Sclerosis

BIIB041 (fampridine)

Phase 3

Multiple Sclerosis, Remittent Progressive

BIIB019 (Daclizumab High Yield Process)

Phase 3

Relapsing-Remitting Multiple Sclerosis

BG9418 (Interferon beta-1a)

Phase 3

Active Ulcerative Colitis

Glatiramer Acetate

Phase 3

Relapsing-Remitting Multiple Sclerosis

fampridine

Phase 3

Multiple Sclerosis

BG00012 (dimethyl fumarate)

Phase 3

Healthy

BG00002 (natalizumab)

Phase 3

Multiple Sclerosis, Relapsing-Remitting

Alefacept

Phase 3

Chronic Plaque Psoriasis

Omaveloxolone

Phase 3

Friedreich Ataxia

Bardoxolone Methyl

Phase 3

Alport Syndrome

Interferon Beta-1a

Phase 3

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Interferon β-1a

Phase 3

Relapsing-Remitting Multiple Sclerosis

tonapofylline

Phase 3

Renal Insufficiency

Diroximel fumarate

Phase 3

Relapsing Forms of Multiple Sclerosis

lixivaptan

Phase 3

Hyponatremia

Sertraline

Phase 3

Depressive Disorder, Major

Rituxan, Cyclophosphamide, Vincristine, Prednisone

Phase 3

Immune Thrombocytopenic Purpura

baricitinib treatment

Phase 3

Rheumatoid Arthritis

Mycophenolate Mofetil (cellcept)

Phase 3

Multiple Sclerosis

anti-TNF therapy

Phase 3

Rheumatoid Arthritis

Anti-inflammatory drugs

Phase 3

Rheumatoid Arthritis

ASA

Phase 3

Healthy

rituximab [MabThera/Rituxan]

Phase 3

Rheumatoid Arthritis

Desvenlafaxine

Phase 3

Depressive Disorder, Major

BIIB033

Phase 2

Multiple Sclerosis

MOR202

Phase 2

Glomerulonephritis

BIIB147

Phase 2

Amyotrophic Lateral Sclerosis

BCNU

Phase 2

Lymphoma

Transitioning patients from cyclosporine to alefacept

Phase 2

Psoriasis

Rituxan

Phase 2

Lymphoma

Bardoxolone methyl capsules

Phase 2

IgA Nephropathy

Mechanism of action of alefacept

Phase 2

Psoriasis

BIIB111

Phase 2

Choroideremia

Levodopa

Phase 2

Parkinson Disease

Chemotherapy and Radioimmunotherapy

Phase 2

Non-Hodgkin Lymphoma

90-Y-ibritumomab tiuxetan

Phase 2

Lymphoma

Bardoxolone Methyl (RTA 402)

Phase 2

Chronic Kidney Disease

natalizumab IV

Phase 2

Relapsing-Remitting Multiple Sclerosis

BG00002-E (natalizumab high titer)

Phase 2

Multiple Sclerosis

Ad.hIFN-β (BG00001, IDEC-201)

Phase 2

Colorectal Carcinoma

IDEC-114

Phase 2

Non-Hodgkin's Lymphoma

tetanus diphtheria toxoids vaccine

Phase 2

Relapsing Forms of Multiple Sclerosis

Baminercept alfa 1

Phase 2

Rheumatoid Arthritis

BIIB074

Phase 2

Primary Inherited Erythromelalgia

VP -16

Phase 2

Lymphoma

Omaveloxolone Capsules (/capsule)

Phase 2

Melanoma

Omaveloxolone Lotion

Phase 2

Breast Cancer

Bardoxolone methyl (amorphous dispersion)

Phase 2

Renal Insufficiency, Chronic

Yttrium-ibritumomab (Zevalin)

Phase 2

Lymphoma, Mantle-Cell

BIIB080

Phase 2

Alzheimer Disease

OrphanFast TrackBreakthrough

Omaveloxolone Ophthalmic

Phase 2

Inflammation and Pain Following Ocular Surgery

APL-3007, pegcetacoplan (APL-2)

Phase 2

Geographic Atrophy Secondary to Age-related Macular Degeneration

RTA 402 (Bardoxolone Methyl)

Phase 2

Diabetic Nephropathy

Antiparkinsonian Agent(s)

Phase 2

Parkinson Disease

Diranersen

Phase 2

Mild Cognitive Impairment Due to Alzheimer's Disease

BIIB059 (litifilimab)

Phase 2

Systemic Lupus Erythematosus

Baminercept alfa 3

Phase 2

Rheumatoid Arthritis

Baminercept alfa 4

Phase 2

Rheumatoid Arthritis

Baminercept alfa 2

Phase 2

Rheumatoid Arthritis

Baminercept alfa 5

Phase 2

Rheumatoid Arthritis

CVP

Phase 2

Non-Hodgkins Lymphoma

In Zevalin

Phase 2

Lymphoma

BG00011

Phase 2

Idiopathic Pulmonary Fibrosis (IPF)

Ibritumomab Tiuxetan

Phase 2

Non-Hodgkins Lymphoma

interferon beta 1-a

Phase 2

Relapsing Remitting Multiple Sclerosis

meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)

Phase 2

Relapsing Forms of Multiple Sclerosis

BIIB033 (anti-LINGO-1 mAb)

Phase 2

Acute Optic Neuritis

DRF

Phase 2

Relapsing Forms of Multiple Sclerosis

exemestane (Aromasin)

Phase 2

Breast Cancer

trivalent seasonal influenza vaccine

Phase 2

Relapsing-Remitting Multiple Sclerosis

BIIB122

Phase 2

Parkinson Disease

Methylprednisolone

Phase 2

Graft Versus Host Disease

Zevalin Radioimmunotherapy

Phase 2

Lymphoma

BIIB091

Phase 2

Relapsing Forms of Multiple Sclerosis

SAGE-324

Phase 2

Essential Tremor

CHOP

Phase 2

Non-Hodgkins Lymphoma

natalizumab SC

Phase 2

Relapsing-Remitting Multiple Sclerosis

Y Zevalin

Phase 2

Lymphoma

Bardoxolone methyl oral capsule

Phase 2

Chronic Kidney Diseases

CNV1014802

Phase 2

Lumbosacral Radiculopathy

BIIB104

Phase 2

Cognitive Impairment Associated With Schizophrenia

Lumiliximab with FCR

Phase 2

Chronic Lymphocytic Leukemia

BG9924

Phase 2

Rheumatoid Arthritis

BIIB021

Phase 2

GIST

Omaveloxolone Opthalmic

Phase 2

Inflammation and Pain Following Ocular Surgery

BIIB041 (PR Fampridine)

Phase 2

Multiple Sclerosis

Zevalin

Phase 2

Lymphoma

90Y Zevalin

Phase 2

Non-Hodgkins Lymphoma

Lecanemab

Phase 2

Alzheimer's Disease

BG00010

Phase 2

Painful Lumbar Radiculopathy

Ibritumomab Tiuxetan (Zevalin)

Phase 2

Lymphoma

BIIB014

Phase 2

Parkinson's Disease

Tyruko Injectable Product

Phase 2

Multiple Sclerosis

BIIB112

Phase 2

X-Linked Retinitis Pigmentosa

Frequently asked questions

What is in Biogen Inc.'s drug pipeline?→

CatalystAlert tracks 121 drug candidates in Biogen Inc.'s (BIIB) pipeline across Phase 3, Phase 2, Approved. Its lead program is Tofersen (Approved). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Biogen Inc.'s next FDA catalyst?→

Biogen Inc.'s (BIIB) next tracked catalyst is a Phase 3 readout expected December 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track BIIB biotech catalysts?→

Add BIIB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Biogen Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply